Melanoma antigen family C1 (MAGE-C1) (MAGE-C1)

Melanoma antigen family C1 (MAGE-C1), also known as CT7, is a prominent member of the cancer-testis antigen (CTA) family, characterized by its restricted expression in the immune-privileged testis and aberrant overexpression in various malignancies [1, 2]. It is most notably expressed in multiple myeloma, where it serves as a critical driver of malignant plasma cell survival and a marker of poor prognosis [1, 9]. Biologically, MAGE-C1 functions as an anti-apoptotic factor and a regulator of the cell cycle, specifically promoting the G2/M phase transition to support rapid tumor cell proliferation [3, 5]. Due to its high tumor specificity and strong immunogenicity, it is a major target for cancer immunotherapies, including mRNA vaccines and T-cell receptor (TCR) engineered T-cell therapies [20, 23]. Clinical strategies often utilize MAGE-C1 to elicit a robust cytotoxic T-lymphocyte response against cancer cells while sparing normal tissues [11, 22]. Furthermore, research indicates that silencing MAGE-C1 can significantly enhance the sensitivity of tumor cells to chemotherapy and proteasome inhibitors like bortezomib [3, 6]. As a result, MAGE-C1 remains a high-priority target for developing personalized and targeted treatments for hematological and solid tumors [7, 27].

Other names

CT7CT7.1Cancer/testis antigen 7.1Melanoma-associated antigen C1Melanoma antigen family C, 1Cancer/testis antigen family 7, member 1

MAGE-C1 is targeted primarily through immunotherapy, where mRNA-based vaccines or T-cell receptor (TCR) engineered T-cells are used to induce a tumor-specific cytotoxic T-lymphocyte response against cells expressing the antigen [20, 23]. Additionally, silencing MAGE-C1 expression can sensitize malignant cells to proteasome inhibitors like bortezomib by promoting apoptosis and disrupting cell cycle progression [3, 6].